Byetta Added to Type 2 Regimens Improves Control
A recent study compared the effect of adding exenatide (Byetta) or insulin glargine (Lantus) to type 2 patients’ treatment regimens. The type 2s previously had been taking metformin and a sulfonylurea with little success.
According to the researchers, patients taking Byetta at dosages of 10 micrograms twice daily achieved reductions in glucose measures similar to those of patients taking Lantus.
“[Byetta] reduced postprandial glucose excursions more than insulin glargine, while insulin glargine reduced fasting glucose concentrations more than [Byetta],” write the researchers.
Byetta patients also lost an average of 5 pounds, while patients on Lantus gained an average of 4 pounds. Rates of symptomatic hypoglycemia were similar between treatment groups.
The most common adverse event for Byetta users was nausea, which was experienced by 57 percent of the participants. Six percent of Byetta participants discontinued its use due to nausea.
—Annals of Internal Medicine, October 18, 2005Click Here To View Or Post Comments